Accurate Education - Synergistic Protocols - Synbiotics + Nutraceuticals

The 4-Domain Approach to Chronic Pain:

Synergistic Protocols – Synbiotics + Nutraceuticals

In the 4-D approach, synbiotics offer a synergistic therapeutic means of targeting the gut-brain axis—a bidirectional communication system linking the enteric nervous system with the central nervous system. Synbiotics demonstrate promising efficacy for chronic pain through modulation of the gut-brain axis, with evidence showing reductions in pain intensity, inflammatory markers, and neuroinflammation. The mechanism involves restoration of gut microbiota balance, increased production of short-chain fatty acids (SCFAs), and reduction of systemic and neuroinflammation.[1][2]

The 4-D protocols are not intended to replace conventional management of chronic pain, but to complement it.

See:

The 4-Domain Approach to Chronic Pain

Gut Health

Synbiotics

Probiotics

Key to Links:

Grey text – handout
Red text – another page on this website
Blue text – Journal publication

Definitions and Terms Related to Pain

—

Synergistic Protocols – Synbiotics + Nutraceuticals

Maximizing the Benefits of Taking Synbiotics with Nutraceuticals

Stack 1: Gut-Brain Axis Optimization

Primary Targets: Neuroinflammation + Peripheral & Central Sensitization

Nutraceutical	Evidence-Based Dose	Timing	Duration	Key Evidence	References
Synbiotic	10⁹–10¹⁰ CFU/day + 6–10 g prebiotic (FOS/inulin)	Morning, with food	8+ weeks	Reduces IL-6, IL-8, TNF-α; modulates gut-brain axis	[1], [2]
PEA (ultramicronized)	600 mg twice daily (1,200 mg/day) × 3 weeks, then 600 mg/day maintenance	Divided doses (morning/evening)	8–12 weeks minimum	SMD -0.98 pain reduction at 8 weeks; effective for nociceptive, neuropathic, and nociplastic pain	[3], [4], [5]
Omega-3 (EPA/DHA)	1–3 g/day combined EPA+DHA; EPA:DHA ratio 1.0 for cytokine reduction	With meals (fat-containing)	6+ months optimal	SMD -0.55 pain reduction; doses ≤1.35 g/day showed SMD -0.60	[6], [7], [8]
Melatonin	3–10 mg/day (start low, titrate up)	30–60 min before bedtime	4–8 weeks	Reduces chronic pain (SMD -0.65); activates SIRT1 in DRG neurons	[9], [10]

Protocol Notes:

PEA: The ultramicronized formulation (um-PEA) is critical for bioavailability. Start with 600 mg twice daily for 3 weeks, then reduce to 600 mg once daily for maintenance. Pain reduction is progressive, with 1.04 points reduction every 2 weeks.[4][5]

Omega-3: A 2025 meta-analysis of 41 RCTs found that lower doses (≤1.35 g/day) were more effective (SMD -0.60) than higher doses (>1.35 g/day, SMD -0.53). EPA:DHA ratios <1.0 produced the greatest cytokine reductions (CRP, TNF-α, IL-6), while ratios ≥1.0 most effectively reduced arachidonic acid.[6][7]

Melatonin: Clinical trials have used doses ranging from 2–12 mg/day. A 2025 RCT used a mean maximal tolerated dose of 11.9 mg/day. Melatonin activates SIRT1 in dorsal root ganglia, improving mitochondrial dysfunction and reducing neuroinflammation.[11][10]

—

Stack 2: Mitochondrial Biogenesis

Primary Target: Mitochondrial Dysfunction

Nutraceutical	Evidence-Based Dose	Timing	Duration	Key Evidence	References
Synbiotic	10⁹–10¹⁰ CFU/day + 6–10 g prebiotic	Morning, with food	8+ weeks	Activates PGC-1α via SCFA; increases butyrate	[1], [2]
Resveratrol	150–500 mg/day (moderate dose preferred)	With meals	8–12 weeks	Activates SIRT1/PGC-1α; moderate doses more effective than high doses	[3], [4], [5], [6]
CoQ10	200–400 mg/day 300–400 mg optimal for inflammation	With fat-containing meals	8+ weeks	Reduces fatigue (Hedges’ g = -0.398); reduces CRP, IL-6, TNF-α	[7], [8], [9], [10]
NAD+ Precursor (NR)	250–500 mg/day	Morning	8+ weeks	Increases NAD+; enhances SIRT1 activity	—
Acetyl-L-Carnitine	1,500–3,000 mg/day (divided doses)	Divided (morning/afternoon)	12+ weeks	Improves neuropathy; enhances fatty acid oxidation	—

Protocol Notes:

Resveratrol: A 2025 GRADE-assessed meta-analysis found that intervention duration significantly influenced SIRT1 activation, with studies <12 weeks showing significant effects on SIRT1 gene expression. Critically, moderate doses are more effective than high doses for mitochondrial benefits—SIRT1 is required for AMPK activation and mitochondrial function improvements.[14][16]

CoQ10: Meta-analysis of 13 RCTs showed significant fatigue reduction (Hedges’ g = -0.398), with dose-dependent effects (coefficient = -0.0017 per mg, p<0.001). For inflammation, 300–400 mg/day showed superior inhibition of CRP, IL-6, and TNF-α. CoQ10 + NADH (200 mg + 20 mg/day) significantly improved fatigue and ATP levels in chronic fatigue syndrome.[20][21][19]

Synbiotic + Resveratrol Synergy: Both activate the SIRT1/PGC-1α pathway through complementary mechanisms—resveratrol via direct LKB1-mediated phosphorylation, and synbiotics via butyrate-mediated HDAC inhibition.[15][12]

—

Stack 3: Antioxidant Defense

Primary Target: Oxidative Stress

Nutraceutical	Evidence-Based Dose	Timing	Duration	Key Evidence	References
Synbiotic	10⁹–10¹⁰ CFU/day + 6–10 g prebiotic	Morning, with food	8+ weeks	↑ TAC by 54 mmol/L, ↑ GSH by 40 μmol/L, ↓ MDA by 0.45 μmol/L	[1], [2]
NAC	600 mg twice daily (1,200 mg/day)	Divided doses	8–12 weeks	↓ MDA (SMD -1.44), ↓ IL-8, ↓ homocysteine; ↓ CRP, ↓ IL-6	[3], [4], [5]
Alpha-Lipoic Acid	600 mg/day (oral)	With meals	5+ weeks	Optimal risk-to-benefit ratio at 600 mg; improves neuropathy symptoms	[6], [7], [8], [9]
Quercetin	500 mg/day	With meals	8 weeks	↓ CRP (WMD -0.33 mg/L); ↓ TNF-α; improves RA symptoms	[10], [11], [12]
Sulforaphane	30–60 mg/day (or 400 mg broccoli sprout extract)	Morning	4–12 weeks	Activates Nrf2; enhances antioxidant enzymes	—

Protocol Notes:

NAC: Meta-analysis of 28 studies showed significant reductions in MDA (SMD -1.44), IL-8 (WMD -2.56 pg/mL), and homocysteine (WMD -1.45 pg/mL). Doses ranged from 400–2,000 mg/day in clinical trials, with 1,200 mg/day being most common. In rheumatoid arthritis, 600 mg twice daily for 3 months reduced oxidative stress markers.[24][25][26]

Alpha-Lipoic Acid: The SYDNEY 2 trial established 600 mg/day as the optimal dose, providing significant symptom improvement with the best risk-to-benefit ratio. Higher doses (1,200–1,800 mg) showed similar efficacy but increased side effects (nausea, vomiting, vertigo). A 2026 meta-analysis confirmed 600 mg/day as particularly effective for paresthesia, numbness, and burning sensations.[29][28]

NAC + ALA Synergy: Combined NAC + alpha-lipoic acid produces a 3.6-fold enhancement of glutathione content compared to either alone.[34]

Quercetin: Meta-analysis showed significant CRP reduction at ≥500 mg/day (WMD -0.34 mg/L). In rheumatoid arthritis, 500 mg/day for 8 weeks significantly reduced TNF-α, morning stiffness, and pain.[31][33]

—

Stack 4: Systemic Inflammation Control

Primary Target: Systemic Inflammation

Nutraceutical	Evidence-Based Dose	Timing	Duration	Key Evidence	References
Synbiotic	10⁹–10¹⁰ CFU/day + 6–10 g prebiotic	Morning, with food	8+ weeks	↓ hs-CRP, ↓ TNF-α, ↓ IL-6, ↓ IL-1β	[1], [2]
Omega-3 (EPA/DHA)	1–3 g/day combined EPA+DHA	With fat-containing meals	6+ months	↓ CRP, ↓ TNF-α, ↓ IL-6; EPA:DHA 1.0 for cytokines	[3], [4], [5]
Curcumin (enhanced bioavailability)	500–1,500 mg/day (BCM-95 or equivalent)	With meals	8–12 weeks	Equivalent to NSAIDs for pain; ↓ inflammation	[6], [7], [8], [9]
Quercetin	500 mg/day	With meals	8 weeks	↓ CRP, ↓ TNF-α; synergistic with probiotics	[10], [11], [12]
Boswellia	300–500 mg 3× daily (900–1,500 mg/day)	With meals	8–12 weeks	↓ 5-LOX; reduces joint inflammation	—

Protocol Notes:

Curcumin: Clinical trials have used doses ranging from 120–1,500 mg/day for 4–36 weeks. The VA/DoD guidelines note that BCM-95 formulation (500 mg TID = 1,500 mg/day) has ~7-fold greater bioavailability than standard curcumin. Curcumin was equivalent to ibuprofen and diclofenac for pain reduction, with significantly fewer adverse events.[37][36]

Curcumin + Synbiotic Synergy: Gut microbiota enhances curcumin bioavailability through biotransformation to active metabolites and protection against degradation. A probiotic drink increased curcumin bioavailability by 35% (AUC) and 52% (Cmax).[40][41][42]

Omega-3 Dosing Nuance: The 2025 meta-analysis found a time-dependent effect—relief was noticeable at 1 month (SMD -0.27) and improved by 6 months (SMD -0.83). For anti-inflammatory effects, 1–3 g/day EPA+DHA showed the most consistent reductions in CRP, TNF-α, and IL-6.[6][7]

—

Comprehensive Daily Dosing Schedule

Optimized daily protocol integrating all 4 stacks:

Morning (with breakfast):

Nutraceutical	Dose	Notes
Synbiotic	10⁹–10¹⁰ CFU + 6–10 g prebiotic	Foundation—start first
B-Complex (with B12)	Standard B-complex	Enhanced absorption with probiotics
Vitamin D3	2,000–5,000 IU	Fat-soluble; take with meal
Omega-3 (EPA/DHA)	1–1.5 g	With fat-containing food
CoQ10	200 mg	With fat-containing food
Nicotinamide Riboside	250–500 mg	NAD+ precursor
P5P	25–50 mg	Active B6 form

Midday (with lunch):

Nutraceutical	Dose	Notes
Curcumin (BCM-95)	500 mg	Enhanced bioavailability formulation
Quercetin	500 mg	Synergistic with probiotics
Boswellia	300–500 mg	5-LOX inhibition
PEA (ultramicronized)	600 mg	First dose of divided dosing
Acetyl-L-Carnitine	750–1,500 mg	First dose
D-Ribose	2.5–5 g	ATP substrate

Afternoon (optional, with snack):

Nutraceutical	Dose	Notes
Sulforaphane	30–60 mg	Nrf2 activation
Taurine	500–1,000 mg	Neuroprotection
Acetyl-L-Carnitine	750–1,500 mg	Second dose

Evening (with dinner):

Nutraceutical	Dose	Notes
Resveratrol	150–250 mg	SIRT1 activation
Alpha-Lipoic Acid	600 mg	Optimal dose per SYDNEY 2
NAC	600 mg	First dose
Omega-3 (EPA/DHA)	0.5–1 g	Second dose if needed
CoQ10	100–200 mg	Second dose if using 300–400 mg/day
Magnesium	200–400 mg	Evening for relaxation/sleep
PEA (ultramicronized)	600 mg	Second dose (first 3 weeks)

Bedtime:

Nutraceutical	Dose	Notes
Melatonin	3–10 mg	30–60 min before sleep; start low
NAC	600 mg	Second dose

—

Domain-Specific Dose Optimization

Domain	Priority Nutraceuticals	Optimal Doses	Duration for Effect	References
Systemic Inflammation	Omega-3, Curcumin, Synbiotic, Quercetin	Omega-3: 1–3 g/day; Curcumin: 1,000–1,500 mg/day; Quercetin: 500 mg/day	8–12 weeks; 6 months optimal for omega-3	[1], [2], [3], [4]
Neuroinflammation	PEA, Melatonin, Synbiotic, Omega-3	PEA: 1,200 mg/day (loading) → 600 mg/day; Melatonin: 3–10 mg/day	4–8 weeks for PEA; ongoing for melatonin	[5], [6], [7], [8]
Oxidative Stress	NAC, ALA, Quercetin, Synbiotic, CoQ10	NAC: 1,200 mg/day; ALA: 600 mg/day; CoQ10: 300–400 mg/day	5–12 weeks	[9], [10], [11]
Mitochondrial Dysfunction	Resveratrol, CoQ10, NR, ALC, Synbiotic	Resveratrol: 150–500 mg/day; CoQ10: 200–400 mg/day; ALC: 1,500–3,000 mg/day	8–12 weeks	[12], [13], [14], [15]
Sensitization	PEA, Synbiotic, Melatonin, Magnesium	PEA: 600–1,200 mg/day; Melatonin: 3–10 mg/day	3–8 weeks	[5], [6], [7]

—

Key Dosing Principles

1. Start with the synbiotic foundation: Take synbiotics consistently for at least 2 weeks before expecting enhanced effects from other nutraceuticals. This establishes the gut environment for optimal bioavailability and synergy.

2. Loading phases for PEA: Use 600 mg twice daily for the first 3 weeks, then reduce to 600 mg once daily for maintenance.[5]

3. Moderate doses often outperform high doses: This is particularly true for resveratrol (moderate doses activate SIRT1 more effectively) and omega-3 (≤1.35 g/day showed greater pain reduction than higher doses).[16][6]

4. Duration matters: Many effects are time-dependent. Omega-3 benefits increase from 1 month (SMD -0.27) to 6 months (SMD -0.83). CoQ10 fatigue reduction correlates with treatment duration (coefficient = -0.0042 per day).[6][20]

5. Bioavailability formulations are critical: Use ultramicronized PEA, BCM-95 or equivalent curcumin, and consider taking fat-soluble compounds (CoQ10, vitamin D, omega-3) with fat-containing meals.

6. Synergistic timing: Take curcumin after synbiotic colonization is established (after 1–2 weeks) to maximize the bidirectional bioavailability enhancement.[40][41][42]

7. Alpha-lipoic acid at 600 mg/day: This is the evidence-based optimal dose, providing the best risk-to-benefit ratio. Higher doses increase side effects without improving efficacy.[29]

References

Synbiotic Supplementation and the Effects on Clinical and Metabolic Responses in Patients With Rheumatoid Arthritis: A Randomised, Double-Blind, Placebo-Controlled Trial. Zamani B, Farshbaf S, Golkar HR, Bahmani F, Asemi Z. The British Journal of Nutrition. 2017;117(8):1095-1102. doi:10.1017/S000711451700085X.
Improvement of Gastrointestinal Discomfort and Inflammatory Status by a Synbiotic in Middle-Aged Adults: A Double-Blind Randomized Placebo-Controlled Trial. Neyrinck AM, Rodriguez J, Taminiau B, et al. Scientific Reports. 2021;11(1):2627. doi:10.1038/s41598-020-80947-1.
Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding. Viña I, López-Moreno M. Nutrition Reviews. 2025;83(7):e1604-e1618. doi:10.1093/nutrit/nuae203.
Ultramicronized N-Palmitoylethanolamine Associated With Analgesics: Effects Against Persistent Pain. Nobili S, Micheli L, Lucarini E, et al. Pharmacology & Therapeutics. 2024;258:108649. doi:10.1016/j.pharmthera.2024.108649.
Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-Analysis. Paladini A, Fusco M, Cenacchi T, et al. Pain Physician. 2016;19(2):11-24.
Effects of Omega-3 Fatty Acids on Chronic Pain: A Systematic Review and Meta-Analysis. Xie L, Wang X, Chu J, et al. Frontiers in Medicine. 2025;12:1654661. doi:10.3389/fmed.2025.1654661.
Role of the EPA: DHA Dosing Ratio in Omega-3 Supplements on Blood Fatty Acid Profiles and Inflammation: A Systematic Review and Meta-Analysis. Khabir Z, Abdelhafez A, Camponovo F, Joyce P, Garcia-Bennett A. Critical Reviews in Food Science and Nutrition. 2026;:1-22. doi:10.1080/10408398.2026.2615693.
Effect of Ω-3 Polyunsaturated Fatty Acids on Arthritic Pain: A systematic Review. Abdulrazaq M, Innes JK, Calder PC. Nutrition (Burbank, Los Angeles County, Calif.). 2017 Jul – Aug;39-40:57-66. doi:10.1016/j.nut.2016.12.003.
Analgesic Efficacy of Melatonin: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials. Oh SN, Myung SK, Jho HJ. Journal of Clinical Medicine. 2020;9(5):E1553. doi:10.3390/jcm9051553.
Melatonin Improves Mitochondrial Dysfunction and Attenuates Neuropathic Pain by Regulating SIRT1 in Dorsal Root Ganglions. Zeng Y, Fang Q, Chen J, et al. Neuroscience. 2023;534:29-40. doi:10.1016/j.neuroscience.2023.10.005.
Melatonin for Neuropathic Pain: A Double-Blind, Placebo-Controlled, Randomized, Crossover Trial. Gilron I, Elkerdawy H, Tu D, et al. Pain. 2025;:00006396-990000000-00905. doi:10.1097/j.pain.0000000000003651.
Next Generation, Modifiable Cardiometabolic Biomarkers: Mitochondrial Adaptation and Metabolic Resilience: A Scientific Statement From the American Heart Association. Mietus-Snyder M, Perak AM, Cheng S, et al. Circulation. 2023;148(22):1827-1845. doi:10.1161/CIR.0000000000001185.
Comprehensive Amelioration of High-Fat Diet-Induced Metabolic Dysfunctions Through Activation of the PGC-1α Pathway by Probiotics Treatment in Mice. Kwon J, Kim B, Lee C, et al. PloS One. 2020;15(2):e0228932. doi:10.1371/journal.pone.0228932.
Impact of Resveratrol Supplementation on Human Sirtuin 1: A Grading of Recommendations Assessment, Development and Evaluation-Assessed Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials. Mansouri F, Feliziani G, Bordoni L, Gabbianelli R. Journal of the Academy of Nutrition and Dietetics. 2025;:S2212-2672(25)00114-5. doi:10.1016/j.jand.2025.03.011.
Resveratrol-Induced Sirt1 Phosphorylation by LKB1 Mediates Mitochondrial Metabolism. Huang Y, Lu J, Zhan L, et al. The Journal of Biological Chemistry. 2021;297(2):100929. doi:10.1016/j.jbc.2021.100929.
SIRT1 Is Required for AMPK Activation and the Beneficial Effects of Resveratrol on Mitochondrial Function. Price NL, Gomes AP, Ling AJ, et al. Cell Metabolism. 2012;15(5):675-90. doi:10.1016/j.cmet.2012.04.003.
Can Resveratrol Modulate Sirtuins in Obesity and Related Diseases? A Systematic Review of Randomized Controlled Trials. Fraiz GM, da Conceição AR, de Souza Vilela DL, et al. European Journal of Nutrition. 2021;60(6):2961-2977. doi:10.1007/s00394-021-02623-y.
Does Coenzyme Q10 Plus Selenium Supplementation Ameliorate Clinical Outcomes by Modulating Oxidative Stress and Inflammation in Individuals With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome?. Castro-Marrero J, Domingo JC, Cordobilla B, et al. Antioxidants & Redox Signaling. 2022;36(10-12):729-739. doi:10.1089/ars.2022.0018.
Does Oral Coenzyme Q10 Plus NADH Supplementation Improve Fatigue and Biochemical Parameters in Chronic Fatigue Syndrome?. Castro-Marrero J, Cordero MD, Segundo MJ, et al. Antioxidants & Redox Signaling. 2015;22(8):679-85. doi:10.1089/ars.2014.6181.
Effectiveness of Coenzyme Q10 Supplementation for Reducing Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Tsai IC, Hsu CW, Chang CH, Tseng PT, Chang KV. Frontiers in Pharmacology. 2022;13:883251. doi:10.3389/fphar.2022.883251.
Efficacy and Optimal Dose of Coenzyme Q10 Supplementation on Inflammation-Related Biomarkers: A GRADE-Assessed Systematic Review and Updated Meta-Analysis of Randomized Controlled Trials. Hou S, Tian Z, Zhao D, et al. Molecular Nutrition & Food Research. 2023;67(13):e2200800. doi:10.1002/mnfr.202200800.
The Effects of Probiotic/Synbiotic Supplementation Compared to Placebo on Biomarkers of Oxidative Stress in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pourrajab B, Fatahi S, Sohouli MH, Găman MA, Shidfar F. Critical Reviews in Food Science and Nutrition. 2022;62(2):490-507. doi:10.1080/10408398.2020.1821166.
The Effects of Probiotic and Synbiotic Supplementation on Inflammation, Oxidative Stress, and Circulating Adiponectin and Leptin Concentration in Subjects With Prediabetes and Type 2 Diabetes Mellitus: A GRADE-assessed Systematic Review, Meta-Analysis, and Meta-Regression of Randomized Clinical Trials. Naseri K, Saadati S, Ghaemi F, et al. European Journal of Nutrition. 2023;62(2):543-561. doi:10.1007/s00394-022-03012-9.
The Effects of N-Acetylcysteine on Inflammatory and Oxidative Stress Biomarkers: A Systematic Review and Meta-Analysis of Controlled Clinical Trials. Faghfouri AH, Zarezadeh M, Tavakoli-Rouzbehani OM, et al. European Journal of Pharmacology. 2020;884:173368. doi:10.1016/j.ejphar.2020.173368.
The Effects of N-Acetylcysteine on Serum Level of Inflammatory Biomarkers in Adults. Findings From a Systematic Review and Meta-Analysis of Randomized Clinical Trials. Askari M, Faryabi R, Mozaffari H, Darooghegi Mofrad M. Cytokine. 2020;135:155239. doi:10.1016/j.cyto.2020.155239.
Effects of N-Acetylcysteine Supplementation on Disease Activity, Oxidative Stress, and Inflammatory and Metabolic Parameters in Rheumatoid Arthritis Patients: A Randomized Double-Blind Placebo-Controlled Trial. Esalatmanesh K, Jamali A, Esalatmanesh R, et al. Amino Acids. 2022;54(3):433-440. doi:10.1007/s00726-022-03134-8.
Alpha-Lipoic Acid for Diabetic Peripheral Neuropathy. Baicus C, Purcarea A, von Elm E, Delcea C, Furtunescu FL. The Cochrane Database of Systematic Reviews. 2024;1:CD012967. doi:10.1002/14651858.CD012967.pub2.
Effectiveness of Alpha Lipoic Acid Supplementation on Biochemical, Clinical, and Inflammatory Parameters in Patients With Diabetic Polyneuropathy: A Systematic Review and Meta-Analysis. Salinas AV, Caroca TM, Santibáñez FP, et al. Diabetes & Metabolic Syndrome. 2026;20(2):103374. doi:10.1016/j.dsx.2026.103374.
Oral Treatment With Alpha-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy: The SYDNEY 2 Trial. Ziegler D, Ametov A, Barinov A, et al. Diabetes Care. 2006;29(11):2365-70. doi:10.2337/dc06-1216.
A Case for Alpha-Lipoic Acid as an Alternative Treatment for Diabetic Polyneuropathy. Nguyen N, Takemoto JK. Journal of Pharmacy & Pharmaceutical Sciences : A Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques. 2018;21(1s):177s-191s. doi:10.18433/jpps30100.
Effects of Supplementation With Quercetin on Plasma C-Reactive Protein Concentrations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mohammadi-Sartang M, Mazloom Z, Sherafatmanesh S, Ghorbani M, Firoozi D. European Journal of Clinical Nutrition. 2017;71(9):1033-1039. doi:10.1038/ejcn.2017.55.
The Effects of Quercetin Supplementation on Lipid Profiles and Inflammatory Markers Among Patients With Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Tabrizi R, Tamtaji OR, Mirhosseini N, et al. Critical Reviews in Food Science and Nutrition. 2020;60(11):1855-1868. doi:10.1080/10408398.2019.1604491.
The Effect of Quercetin on Inflammatory Factors and Clinical Symptoms in Women With Rheumatoid Arthritis: A Double-Blind, Randomized Controlled Trial. Javadi F, Ahmadzadeh A, Eghtesadi S, et al. Journal of the American College of Nutrition. 2017;36(1):9-15. doi:10.1080/07315724.2016.1140093.
Effect of Single and Combined Supply of Glutamine, Glycine, N-Acetylcysteine, and R,s-Alpha-Lipoic Acid on Glutathione Content of Myelomonocytic Cells. Wessner B, Strasser EM, Spittler A, Roth E. Clinical Nutrition (Edinburgh, Scotland). 2003;22(6):515-22. doi:10.1016/s0261-5614(03)00053-0.
The Effects of Synbiotics Surpass Prebiotics in Improving Inflammatory Biomarkers in Children and Adults: A Systematic Review, Meta-Analysis, and Meta-Evidence of Data From 5,207 Participants in 90 Randomized Controlled Trials. Zhang Y, Hong J, Zhang Y, Gao Y, Liang L. Pharmacological Research. 2025;:107832. doi:10.1016/j.phrs.2025.107832.
The Non-Surgical Management of Hip & Knee Osteoarthritis (OA) (2020). Matthew Bair MD MS, John Cody MD, Jess Edison MD, et al. Department of Veterans Affairs.
Efficacy and Safety of Curcumin and Extract in the Treatment of Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trial. Zeng L, Yang T, Yang K, et al. Frontiers in Immunology. 2022;13:891822. doi:10.3389/fimmu.2022.891822.
The Analgesic Effect of Curcumin and Nano-Curcumin in Clinical and Preclinical Studies: A Systematic Review and Meta-Analysis. Hajimirzaei P, Eyni H, Razmgir M, et al. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2025;398(1):393-416. doi:10.1007/s00210-024-03369-0.
Curcuma as an Anti-Inflammatory Component in Treating Osteoarthritis. Koroljević ZD, Jordan K, Ivković J, Bender DV, Perić P. Rheumatology International. 2023;43(4):589-616. doi:10.1007/s00296-022-05244-8.
In Vivo Investigation on the Effect of Gut Microbiota on the Distribution and Biotransformation of Curcumin. Luo F, Chen J, Liang S, et al. Journal of Agricultural and Food Chemistry. 2025;. doi:10.1021/acs.jafc.5c09992.
Unveiling the Role of Gut Microbiota in Curcumin Metabolism Using Antibiotic-Treated Mice. Luo M, Han Y, Chen Y, et al. Food Chemistry. 2024;460(Pt 2):140706. doi:10.1016/j.foodchem.2024.140706.
The Influence of Food Matrices on the Bioavailability of Curcuminoids From a Dried Colloidal Turmeric Suspension: A Randomized, Crossover, Clinical Trial. Schönenberger KA, Ranzini C, Laval J, et al. Food & Function. 2025;16(2):774-784. doi:10.1039/d4fo03414g.

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.